Skip to Main Content

Three years after the University of California and the Broad Institute began battling over key patents on CRISPR-Cas9 genome editing inventions, the fat lady is finally about to sing in this multimillion-dollar operatic battle.

The U.S. Court of Appeals for the Federal Circuit, which heard oral arguments in the case on Monday, is expected to rule within 90 days on whether the Broad can keep its foundational CRISPR patents, as the patent office ruled last year. (IP experts think the chances of the Supreme Court accepting the case, if the losing party tries that route, are comparable to those of the Baltimore Orioles winning the 2018 World Series.)

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!